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Is There a Role for Intraoperative Radiation Therapy in Patients
with Resected Pancreatic Adenocarcinoma?
Jeffrey J. Meyer, MD and Christopher H. Crane, MD
Department of Radiation Oncology, Unit 97, U.T. M.D. Anderson Cancer Center, Houston, TX
The value of adjuvant radiotherapy is well established in
many tumor sites and is commonly used when pathologic
features of a patient’s primary tumor place them at sufﬁ-
ciently high risk for local-regional recurrence to warrant
additional intervention. The rationale for the use of adju-
vant radiotherapy in such situations is the traditional shared
goal of the surgical and radiation oncologist: to optimize
local-regional control. Attaining local-regional control
prevents the morbidity of a local recurrence, and, in some
situations, improves overall survival, perhaps best exem-
pliﬁed in the case of postmastectomy radiotherapy for
women with high-risk breast cancer.
1 For pancreatic cancer
management, adjuvant radiation has been delivered
through fractionated external beam radiation treatments
(EBRT) and/or single-fraction high-dose intraoperative
radiation therapy (IORT). IORT has the beneﬁt of directly
moving critical normal tissues of the upper abdomen away
from the radiation beam.
2
Prevention of local recurrence leading to an improve-
ment in survival may result through a number of
mechanisms. The most straightforward of these is the
underappreciated fact that local recurrence, particularly at
certain sites such as the head and neck, can itself lead to
disease-speciﬁc mortality. Also, radiation can sterilize
remaining cells able to proliferate at the local site and then
metastasize, causing eventual death; this may be all the
more important in light of evidence suggesting that cells
can be modulated by the postoperative microenvironment
to yield more a more aggressive phenotype, as has recently
been suggested in breast cancer.
3–5 Another, highly
intriguing, possible effect is for irradiation of local tumor
cells to induce abscopal, immune-related killing effects on
distant sites of micrometastases.
5,6
Attaining local-regional control is all the more para-
mount when patterns of cancer failure are predominantly
local-regional and/or reasonably effective chemotherapy is
available to treat systemic micrometastatic disease but not
sterilize local-regional disease. Therein lies the controversy
over adjuvant radiotherapy (be it EBRT or IORT) for
resectable pancreatic adenocarcinoma. Although clinical
and autopsy series have revealed local-regional (tumor bed
and regional lymph nodes) failure to be a common event
(50% or greater) following pancreaticoduodenectomy, it is
much less common for these failures to be in isolation with
respect to distant disease and also for the local-regional
failure itself to be the clear proximate cause of death.
7–9
Acknowledging the high rates of distant failure (liver,
peritoneal cavity), the value of primary radical surgery in
patients with resectable disease may itself be questioned.
10
Two randomized trials provide evidence that surgery does
improve long-term survival rates compared with bypass
intervention or primary chemotherapy and concurrent
radiation.
11,12 However, true long-term disease-free survi-
vorship (apparent cure) is uncommon with surgery alone,
and the need for effective systemic therapies is obvious.
The recently reported CONKO-001 trial showed that
gemcitabine following surgery delays disease failure and
also likely provides higher long-term survival rates (esti-
mated 5-year disease-free survival of 16% vs 6.5% with
surgery alone).
13 Whether additional locally directed
therapies beyond surgery add meaningful beneﬁt—in the
context of contemporary systemic therapy options—
remains an open question. Although the role of adjuvant
chemoradiotherapy was established in an early Gastroin-
testinal Tumor Study Group trial and through retrospective
institutional reports,
14,15 the actual value of the radiation
component has been called into question, most recently by
the controversial ESPAC results.
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IORT ± EBRT for resectable pancreatic cancer? In this
issue of the Annals of Surgical Oncology, investigators
from the Thomas Jefferson University departments of
Radiation Oncology and Surgery report their experience
with 83 patients with resected pancreatic cancer treated
between 1995 and 2005. Of these, 37 patients were treated
with IORT; about 75% of this group also received EBRT,
and 84% received adjuvant chemotherapy. In the group
treated with resection but without IORT, about two-thirds
underwent adjuvant EBRT and chemotherapy. IORT did
not signiﬁcantly increase perioperative complication rates.
As patients were not randomized to the use of IORT, the
authors used a propensity score adjustment in their analysis
of disease control to account for differing prognostic fac-
tors between the two groups. Although IORT was
associated with an odds ratio of 0.41 for local-regional
recurrence, this reduction did not reach statistical signiﬁ-
cance (P = .23). The conﬁdence intervals for this ratio
were quite large (0.10–10.30), reﬂecting patient numbers.
IORT was not associated with improved survival.
Institutional reports and a randomized trial have shown
surgery followed by IORT to yield lower local-regional
recurrence rates compared with surgery alone, although a
positive impact on survival has not been readily demon-
strated.
17–19 As the authors appropriately address,
improvements in systemic therapy are generally necessary
before prevention of local recurrence translates into a
survival beneﬁt.
20 As long as the best systemic therapy
options provide only modest control of distant disease,
local tumor control improvements will not translate into a
survival beneﬁt. Finally, the emergence of novel chemo-
therapeutic or targeted agents that impact distant
metastases may also eventually impact local-regional
microscopic disease control to the degree that adjuvant
radiation may not be needed following R0 resection.
21
Whether or not IORT contributes to overall survival was
also evaluated in a group of patients treated at the Uni-
versity of Texas M.D. Anderson Cancer Center with
neoadjuvant chemoradiation for radiographically resect-
able pancreatic cancer (no tumor involvement of the celiac
axis or superior mesenteric artery with patent portal venous
conﬂuence). The authors reported local recurrence to be a
component of the ﬁrst site of failure in 9% in patients
undergoing neoadjuvant fractionated EBRT (30–50 Gy)
followed by surgery without IORT compared with 4% with
the addition of IORT.
22 The contribution of neoadjuvant
EBRT to surgery cannot be determined in this study.
However, the risk of local recurrence without IORT was
too low in this study to see a clinically meaningful beneﬁt
in survival. In part due to these results, IORT for resected
pancreatic cancer was abandoned at the M.D. Anderson
Cancer Center.
It is interesting to contrast these two large experiences
using IORT for localized pancreatic cancer. In the current
study, positive margins (R1 or R2) occurred in 30 of 83
patients (36%) overall, and the local tumor recurrence rate
was numerically lower in the higher-risk IORT group (23%
versus 39%). Statistical power was limited because of
small numbers, but there was a suggestion that IORT
improved local tumor control. In contrast, 16 of 132
patients (12%) with radiographically resectable tumors that
were treated with neoadjuvant chemoradiation had positive
margins (all R1) in the M.D. Anderson experience, and the
crude local tumor recurrence rate was 4% with IORT and
9% without IORT. The absolute differences in the rates of
positive margins and local tumor recurrence are most likely
the result of differences in patient selection. However, the
comparison illustrates the point that statistically nonsig-
niﬁcant improvements in local tumor control have been
seen with the addition of IORT to resection and standard
adjuvant therapies in cohorts whose combined local
recurrence risk was low (\10% in the M.D. Anderson
study) and moderate (30–40% in the current study).
However, a local control improvement due to IORT large
enough to translate into a survival beneﬁt in pancreatic
cancer is probably only possible in a cohort of the highest-
risk patients (R1/R2 resections) and perhaps even then only
in concert with improved systemic therapy. That hypoth-
esis has yet to be tested.
Where does that leave us when considering the treat-
ment of our next patient? IORT appears to reduce or at
least delay local tumor recurrence in patients undergoing
pancreaticoduodenectomy. The absolute local control
beneﬁt depends on the a priori risk of local recurrence.
Patients undergoing R0 resection treated with standard
adjuvant therapies do not appear to beneﬁt from IORT.
IORT should only be considered in patients who are judged
to have incompletely resected disease (R1 or R2 resections)
intraoperatively. Although a dedicated study of the impact
of IORT following R1/R2 resection has not been per-
formed, IORT should continue to be explored in this
subgroup in parallel with novel systemic therapies.
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